Compare Equinix Inc (EQIX) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs TransMedics Group Inc — how do they compare? Equinix Inc trades at $1,065 (market cap $101.87B), while TransMedics Group Inc trades at $87 (market cap $3.10B). The key difference: Equinix Inc is far larger — about 32.9× TransMedics Group Inc's market cap, and Equinix Inc pays a 2% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| EQIX | TMDX | |
|---|---|---|
Market Cap | $101.87B | $3.10B |
Sector | Real Estate | Technology |
52-Week High | $1.12K | $150.42 |
52-Week Low | $726.09 | $61.99 |
Enterprise Value | $123.00B | $3.49B |
Dividend Yield | 2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,069.17, up 2.47% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 EPS of $4.83, beating estimates, and raised its long-term growth outlook amid strong AI infrastructure demand. Revenue grew to $9.22 billion in 2025, with net income margin improving to 15.63%. However, valuation multiples like P/E of 66.44 and EV/EBITDA of 27.58 are elevated, and net cash flow turned negative in 2025 due to heavy investing activities.
The outlook is supported by robust analyst sentiment with a $1,120 consensus price target and 74.51% buy ratings, but risks include high leverage with debt-to-asset ratio rising to 47.13% in 2025 and earnings misses in two of the last three quarters. Investors should weigh growth potential against valuation and execution risks.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
